TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24406570

Group type: EXPERIMENTAL
Intervention: Vitamin K1
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22450889

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study: 19410094

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MTA Branco
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MTA BIO
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: white Portland cement + 20% bismuth oxide (PC1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: white Portland cement + 10% calcium chloride (PC2)
Number of subjects: 5
Study: 17123297

Group type: EXPERIMENTAL
Intervention: Surgical first stage lead placement (FSLP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Percutaneous needle electrode (PNE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FSLP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FSLP and PNE responders
Number of subjects: 30
Study: 16377603

Group type: COMPARATOR
Intervention: Single, untailored smoking cessation guide (SU)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Single, tailored smoking cessation guide (ST)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Multiple tailored printed materials (MT)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Multiple tailored printed materials with interim data (MRT)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Multiple message group conditions (MT + MRT)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: MRT materials
Number of subjects: 1978
Study: 16563599

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard ACLS measures
Number of subjects: 50
Study: 10565450

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM) patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 8727452

Group type: EXPERIMENTAL
Intervention: MedX lumbar‐extension machine, isotonic exercises two times per week, reduced to one time per week, average length of treatment 97 days and 20 visits.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy asymptomatic geriatric females (HEAL)
Number of subjects: 0
Study: 1364779

Group type: EXPERIMENTAL
Intervention: MR tomography
Number of subjects: 64
Study: 6405908

Group type: EXPERIMENTAL
Intervention: Short term outpatient treatment programme of eclectic orientation
Number of subjects: 30
Study: 30797646

Group type: EXPERIMENTAL
Intervention: Carbohydrate reduced hospital diet (CRD) of 135 g/d
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-carbohydrate reduced hospital diet (NCRD)
Number of subjects: 62
Study: 28614953

Group type: EXPERIMENTAL
Intervention: Forced-Air Warming (FAW)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study: 27161546

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg
Number of subjects: 290

Group type: COMPARATOR
Intervention: Candesartan 8 mg
Number of subjects: 290
Study: 25238424

Group type: EXPERIMENTAL
Intervention: Holmium:Yttrium aluminum garnet (YAG) laser delivery system (LDS) used for transmyocardial revascularization (TMR)
Number of subjects: 42
Study: 22213153

Group type: EXPERIMENTAL
Intervention: Enzastaurin (loading dose 1125 mg, followed by 500 mg/d) with 5-fluorouracil/leucovorin plus bevacizumab
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo with 5-fluorouracil/leucovorin plus bevacizumab
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 19959339

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312

Group type: COMPARATOR
Intervention: Paliperidone palmitate and Placebo
Number of subjects: 312
Study: 18306904

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (16 mg/die for the first 7 days, then 8 mg die for another 7 days, and finally 4 mg die for another 7 days) plus conventional therapy (bronchodilators and inhaled corticosteroids)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (conventional therapy only)
Number of subjects: 28
Study: 15677559

Group type: EXPERIMENTAL
Intervention: ATRA and idarubicin induction followed by 3 polychemotherapy consolidation courses
Number of subjects: 124
Study: 12100834

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) support intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard group support
Number of subjects: 181
Study: 10419912

Group type: EXPERIMENTAL
Intervention: Omeprazole therapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: Antireflux surgery (ARS)
Number of subjects: 310
Study: 7481482

Group type: EXPERIMENTAL
Intervention: Mineral water baths and hot native mineral mud packs (Group I)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mineral water baths and rinsed mineral-free mud packs (Group II)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tap water baths and mineral-free mud packs (Group III)
Number of subjects: 33
Study: 31813973

Group type: EXPERIMENTAL
Intervention: Robotic technique
Number of subjects: 454

Group type: COMPARATOR
Intervention: Frame-based technique
Number of subjects: 454

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 454

Group type: COMPARATOR
Intervention: CTA
Number of subjects: 454

Group type: COMPARATOR
Intervention: Angiogram
Number of subjects: 454
Study: 31368415

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 0
Study: 27871945

Group type: EXPERIMENTAL
Intervention: Diet priming (image of a slim model associated with dieting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (image of an animal unrelated to dieting)
Number of subjects: 0
Study: 25918149

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DHAPQ)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine plus Amodiaquine (SPAQ)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Control group (250 children outside the trial)
Number of subjects: 1499
Study: 23412587

Group type: EXPERIMENTAL
Intervention: propofol-remifentanil
Number of subjects: 29

Group type: COMPARATOR
Intervention: propofol-fentanyl
Number of subjects: 29
Study: 21127894

Group type: EXPERIMENTAL
Intervention: Isometric bilateral knee extension at 45°
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isometric unilateral knee extension
Number of subjects: 10
Study: 18042668

Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation (graded intakes from 2.5 to 12.5 mg.kg(‐1).day(‐1))
Number of subjects: 6
Study: 15921224

Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Dilators
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Side Strip Nasal Dilators
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12442931

Group type: EXPERIMENTAL
Intervention: Sufentanil 8 mL bolus, followed by infusion at 5 mL h(‐1) of a mixture containing sufentanil 1 microg mL(‐1) and bupivacaine 1 mg mL(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl 8 mL bolus, followed by infusion at 5 mL h(‐1) of a solution containing fentanyl 3.5 microg mL(‐1) and bupivacaine 1 mg mL(‐1)
Number of subjects: 90
Study: 10502164

Group type: EXPERIMENTAL
Intervention: Disposable-sheath endoscope system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard endoscope
Number of subjects: 100
Study: 9124784

Group type: EXPERIMENTAL
Intervention: Transabdominal preperitoneal laparoscopic repair (group L) with 3 x 5 inch polypropylene mesh
Number of subjects: 70

Group type: COMPARATOR
Intervention: Shouldice repair (group S)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transabdominal preperitoneal laparoscopic repair (group L)
Number of subjects: 70
Study: 1834037

Group type: EXPERIMENTAL
Intervention: Group I trained at 36 degrees/sec with 20 or 60 repetitions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group II did 20 repetitions at 36 degrees/sec with one limb and 60 repetitions at 108 degrees/sec contralaterally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group III trained at 108 degrees/sec with 20 or 60 repetitions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group IV did no training (control group)
Number of subjects: 20
Study: 6416514

Group type: EXPERIMENTAL
Intervention: overnight supplementary nasogastric tube feeding (4.2 MJ (1000 kcal), including 28 g protein) in addition to normal ward diet
Number of subjects: 122

Group type: COMPARATOR
Intervention: normal ward diet (control)
Number of subjects: 122
Study: 31864393

Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF) plus losartan
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo plus losartan
Number of subjects: 632
Study: 29701878

Group type: EXPERIMENTAL
Intervention: Volume-based protocol with protein supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard nutrition care (hourly-rate-based protocol, without protein supplementation)
Number of subjects: 60
Study: 27434221

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 21

Group type: COMPARATOR
Intervention: GLP-1 receptor antagonist Exendin 9-39 (Ex-9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: DPP-4 inhibitor sitagliptin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Combined blockade of GLP-1 and PYY actions (Ex-9 and sitagliptin)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25112081

Group type: EXPERIMENTAL
Intervention: Acupuncture at Suliao (GV 25)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Acupuncture at Shuigou (GV 26)
Number of subjects: 82
Study: 21382967

Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 47

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 47
Study: 19619378

Group type: EXPERIMENTAL
Intervention: Art therapy (5 sessions over a 5-week period during postoperative radiotherapy)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no art therapy)
Number of subjects: 41
Study: 18827063

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in octogenarians
Number of subjects: 330

Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) in patients <80 years
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Combined clinical score (CCS) for CRT response in octogenarians
Number of subjects: 330

Group type: COMPARATOR
Intervention: Combined clinical score (CCS) for CRT response in patients <80 years
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Composite endpoints of cardiovascular death or hospitalization for major cardiovascular events
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Composite endpoints of cardiovascular death or heart failure hospitalization
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Total mortality
Number of subjects: 330
Study: 16020650

Group type: EXPERIMENTAL
Intervention: Different statistical techniques for recurrent event data analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naive techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical techniques that consider recurrent events
Number of subjects: 0
Study: 12008787

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine/zidovudine
Number of subjects: 173

Group type: COMPARATOR
Intervention: lamivudine/zidovudine
Number of subjects: 173
Study: 9893071

Group type: EXPERIMENTAL
Intervention: Daughters of mothers with established osteoporosis ('fracture' or 'low BMD')
Number of subjects: 207

Group type: COMPARATOR
Intervention: Daughters of mothers at lower risk of osteoporosis ('normal BMD')
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Premenopausal daughters of mothers with established osteoporosis
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Postmenopausal daughters of mothers with established osteoporosis
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: All daughters
Number of subjects: 207
Study: 8775472

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet plus ursodeoxycholic acid (900 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet plus simvastatin (40 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (Diet alone)
Number of subjects: 6
Study: 2280855

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg/b.i.d./i.v.)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Heparin (5000 UI/t.i.d./s.c.)
Number of subjects: 41
Study: 367678

Group type: EXPERIMENTAL
Intervention: Atenolol alone (100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol-chlorthalidone combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol added to chlorthalidone (100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of atenolol
Number of subjects: 0
Study: 31433858

Group type: EXPERIMENTAL
Intervention: Principal components analysis (PCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robustness of the PC's
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing PC's
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization tests
Number of subjects: 0
Study: 30268031

Group type: EXPERIMENTAL
Intervention: Vitrified with Gap26 (vitrified-peptide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrified without Gap26 (vitrified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-vitrified)
Number of subjects: 0
Study: 27217446

Group type: COMPARATOR
Intervention: Bevacizumab (15 mg/kg intravenously once every 3 weeks)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) plus Fosbretabulin (60 mg/m(2) intravenously once every 3 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Fosbretabulin
Number of subjects: 107
Study: 25041873

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous femoral nerve block
Number of subjects: 100
Study: 22902784

Group type: EXPERIMENTAL
Intervention: Self-administered intradermal influenza vaccine
Number of subjects: 228

Group type: COMPARATOR
Intervention: Nurse-administered intradermal influenza vaccine
Number of subjects: 228
Study: 21711479

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on demand
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tadalafil 5 mg once-a-day
Number of subjects: 44
Study: 17661855

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham therapeutic touch
Number of subjects: 82
Study: 15948696

Group type: EXPERIMENTAL
Intervention: Enhanced root planing (group 1, 4 IF; group 2, 8 IF; etc.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enhanced root planing (group 2, higher IF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enhanced root planing (group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Initial scaling and root planing (SRP) (group 3, controls)
Number of subjects: 37
Study: 12585184

Group type: EXPERIMENTAL
Intervention: Jianweishu Granule (JWSG) decocted separately
Number of subjects: 100

Group type: COMPARATOR
Intervention: Jianweishu Granule (JWSG) decocted mingly
Number of subjects: 100
Study: 10349693

Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon plus placebo for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon plus placebo for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study: 7577281

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol
Number of subjects: 160
Study: 2030191

Group type: EXPERIMENTAL
Intervention: Precontemplation stage
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Contemplation stage
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Preparation stage
Number of subjects: 1466

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Stage differences
Number of subjects: 1466
Study: 7093590

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 130

Group type: COMPARATOR
Intervention: ECT
Number of subjects: 130
Study: 31956904

Group type: EXPERIMENTAL
Intervention: Eye Tracking Technology (ETT)
Number of subjects: 25
Study: 29155504

Group type: EXPERIMENTAL
Intervention: Cervical funneling
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Intra-amniotic debris
Number of subjects: 657
Study: 27505467

Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study: 24290423

Group type: EXPERIMENTAL
Intervention: Interventional fetal medicine randomised controlled trial (RCT)
Number of subjects: 7
Study: 23315766

Group type: EXPERIMENTAL
Intervention: Tyrosine (100mg/kg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Milk sugar (placebo)
Number of subjects: 50
Study: 20213469

Group type: EXPERIMENTAL
Intervention: Maximal agonist torque estimated from resultant and antagonist torques in plantar-flexion (PF) and dorsi-flexion (DF).
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Relative torque during all postural tasks.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EMG activity of triceps surae and tibialis anterior muscles during maximal contractions and postural tasks.
Number of subjects: 14
Study: 19002271

Group type: EXPERIMENTAL
Intervention: Capecitabine plus docetaxel (XT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab with capecitabine plus docetaxel (HXT)
Number of subjects: 0
Study: 16651157

Group type: EXPERIMENTAL
Intervention: BioScrew (PLLA screws)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metal screws
Number of subjects: 41
Study: 12782063

Group type: EXPERIMENTAL
Intervention: Perception of configural information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recognition tasks
Number of subjects: 0
Study: 10831026

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment (100-300 mg/day) for 10 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 32
Study: 8624271

Group type: EXPERIMENTAL
Intervention: melphalan + prednisone (MP) for stage I
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: melphalan + prednisone (MP) for stage II
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: melphalan + prednisone (MP) vs peptichemio, vincristine and prednisone for stage III
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Response to 6 months of first-line chemotherapy
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: British Medical Research Council staging system
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Composite parameter integrating percentage of bone marrow plasma cells with cytological features
Number of subjects: 231
Study: 1565444

Group type: COMPARATOR
Intervention: No cryotherapy (control group)
Number of subjects: 2916
Study: 6588179

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full coverage splints
Number of subjects: 30
Study: 30610155

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily for 3 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30314787

Group type: EXPERIMENTAL
Intervention: Intervention: if-then plans (implementation intentions)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control: setting relevant goals
Number of subjects: 106
Study: 26866364

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg daily during chemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 70
Study: 24961324

Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml, 4 mg/ml) as monotherapy for 10 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dextranes and pentoxyphyllin (100 mg/day)
Number of subjects: 80
Study: 22177175

Group type: EXPERIMENTAL
Intervention: Quartz head contact fiber
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard side firing fiber
Number of subjects: 120
Study: 20040339

Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg under fed conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alogliptin 100 mg under fasted conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg q.d. + Metformin 1,000 mg b.i.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg q.d. + Cimetidine 400 mg q.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alogliptin 100 mg q.d. alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg q.d. + Metformin 1,000 mg b.i.d. and Alogliptin 100 mg q.d. + Cimetidine 400 mg q.d.
Number of subjects: 36
Study: 17622869

Group type: EXPERIMENTAL
Intervention: Intermittent feeding regimen (one‐sixth of daily needs infused every 4 hours)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Continuous feeding regimen (drip feeding)
Number of subjects: 164
Study: 16239123

Group type: EXPERIMENTAL
Intervention: Excorim immunoadsorption (IA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 0
Study: 12087006

Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 12 months
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Gluten reexposure for 12 months
Number of subjects: 7

Group type: COMPARATOR
Intervention: Historical control cohort
Number of subjects: 7
Study: 10548325

Group type: EXPERIMENTAL
Intervention: Arizona Food Frequency Questionnaire (AFFQ) administered at baseline and year 1
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Arizona Food Frequency Questionnaire (AFFQ) compared with 4‐day dietary records
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Combined data from both AFFQs compared with diet records
Number of subjects: 139